Biofrontera Stock Today

BFRI Stock  USD 0.88  0.10  10.20%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 85

 
High
 
Low
Very High
Biofrontera is trading at 0.88 as of the 7th of November 2024. This is a 10.2 percent decrease since the beginning of the trading day. The stock's open price was 0.98. Biofrontera has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Biofrontera are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of May 2024 and ending today, the 7th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of October 2021
Category
Healthcare
Classification
Health Care
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. The company has 5.54 M outstanding shares of which 473.76 K shares are currently shorted by private and institutional investors with about 0.82 trading days to cover. More on Biofrontera

Moving against Biofrontera Stock

  0.65GNFT GenfitPairCorr
  0.64BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.55GILD Gilead SciencesPairCorr
  0.47VRDN Viridian TherapeuticsPairCorr

Biofrontera Stock Highlights

President CEOHermann Luebbert
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.631.2198
Way Down
Slightly volatile
Gross Profit Margin0.540.4568
Fairly Up
Slightly volatile
Total Current Liabilities15.2 M18.1 M
Fairly Down
Slightly volatile
Non Current Liabilities Total4.8 M5.1 M
Notably Down
Slightly volatile
Total Assets40.7 M27.9 M
Way Up
Slightly volatile
Total Current Assets34.2 M23.1 M
Way Up
Slightly volatile
Debt Levels
Biofrontera can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biofrontera's financial leverage. It provides some insight into what part of Biofrontera's total assets is financed by creditors.
Liquidity
Biofrontera currently holds 5.4 M in liabilities. Biofrontera has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biofrontera's use of debt, we should always consider it together with its cash and equity.

Free Cash Flow

(26.14 Million)
Biofrontera (BFRI) is traded on NASDAQ Exchange in USA. It is located in 120 Presidential Way, Woburn, MA, United States, 01801 and employs 83 people. Biofrontera is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.42 M. Biofrontera conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.54 M outstanding shares of which 473.76 K shares are currently shorted by private and institutional investors with about 0.82 trading days to cover. Biofrontera currently holds about 31.91 M in cash with (24.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Biofrontera Probability Of Bankruptcy
Ownership Allocation
Biofrontera retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Biofrontera Ownership Details

Biofrontera Stock Institutional Holders

InstituionRecorded OnShares
Royal Bank Of Canada2024-06-30
11.0
Renaissance Technologies Corp2024-06-30
0.0
Xtx Topco Ltd2024-06-30
0.0
Hrt Financial Llc2024-06-30
0.0
Aigh Capital Management, Llc2024-06-30
501.4 K
Rosalind Advisors, Inc.2024-09-30
495.5 K
Scotia Capital Inc2024-06-30
120 K
Geode Capital Management, Llc2024-06-30
17.5 K
Tower Research Capital Llc2024-06-30
10.5 K
Ubs Group Ag2024-06-30
10 K
Blackrock Inc2024-06-30
4.6 K
View Biofrontera Diagnostics

Biofrontera Historical Income Statement

As of now, Biofrontera's Tax Provision is increasing as compared to previous years. The Biofrontera's current Depreciation And Amortization is estimated to increase to about 1.5 M, while Net Interest Income is projected to decrease to (305.6 K). View More Fundamentals

Biofrontera Stock Against Markets

Biofrontera Corporate Management

Daniel JDGeneral ComplianceProfile
Jon MBAVice AffairsProfile
Erica CPACOO, CEOProfile
Jeff HolmHead DevelProfile
Mark BaldygaHead MarketingProfile
Alycia TorresVice AdministrationProfile
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.74)
Revenue Per Share
11.573
Quarterly Revenue Growth
0.34
Return On Assets
(0.40)
Return On Equity
(1.49)
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.